Survodutide 5mg/3mL

What is Survodutide?

Survodutide is an investigational dual-receptor agonist targeting both GLP-1 (glucagon-like peptide-1) and glucagon receptors, making it a unique compound in the landscape of metabolic research. Unlike single-receptor GLP-1 agonists, Survodutide's dual mechanism is designed to simultaneously address appetite regulation and energy expenditure — two critical pillars of metabolic health research.

Researchers are particularly interested in Survodutide's glucagon receptor component, which may drive enhanced energy burning beyond what GLP-1 activation alone can achieve.

Mechanism of Action

Survodutide is being studied for its potential to influence:

• GLP-1 receptor activation — supports satiety signaling, slows gastric emptying, and promotes insulin secretion
• Glucagon receptor activation — promotes energy expenditure and hepatic fat metabolism
• Dual-pathway metabolic regulation — combined receptor engagement targeting both appetite and caloric utilization
• Hepatic lipid metabolism — glucagon signaling may support liver fat reduction in research models

Areas of Research

Current clinical and preclinical studies are evaluating Survodutide's potential role in:

• Obesity and body weight management research
• Non-alcoholic fatty liver disease (NAFLD/NASH) research
• Metabolic function and energy balance
• Appetite control and food intake reduction

Research Use Only

This product is intended for laboratory research purposes only. It is not intended for human consumption, medical use, diagnosis, cure, mitigation, treatment, or prevention of any disease. This product has not been evaluated by the U.S. Food and Drug Administration (FDA). Purchasers are responsible for compliance with all applicable laws and regulations regarding the use and handling of research materials.